#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Feline leukaemia virus ( FeLV ) is a gammaretrovirus that infects domestic cats and closely related wild felids worldwide .
3-1	17-23	Feline	animal|abstract[5]	new|new[5]	appos|coref|appos|coref	3-5[0_5]|4-11|3-5[0_5]|4-11
3-2	24-33	leukaemia	abstract|abstract[5]	new|new[5]	_	_
3-3	34-39	virus	abstract[5]	new[5]	_	_
3-4	40-41	(	_	_	_	_
3-5	42-46	FeLV	abstract	giv	coref	3-8[7_0]
3-6	47-48	)	_	_	_	_
3-7	49-51	is	_	_	_	_
3-8	52-53	a	abstract[7]	giv[7]	coref	4-6[11_7]
3-9	54-69	gammaretrovirus	abstract[7]	giv[7]	_	_
3-10	70-74	that	_	_	_	_
3-11	75-82	infects	_	_	_	_
3-12	83-91	domestic	animal[8]	new[8]	coref	5-9[24_8]
3-13	92-96	cats	animal[8]	new[8]	_	_
3-14	97-100	and	_	_	_	_
3-15	101-108	closely	_	_	_	_
3-16	109-116	related	_	_	_	_
3-17	117-121	wild	animal[9]	new[9]	_	_
3-18	122-128	felids	animal[9]	new[9]	_	_
3-19	129-138	worldwide	_	_	_	_
3-20	139-140	.	_	_	_	_

#Text=Since the first description of the virus in 1964 in feline lymphoma tissue , increasing knowledge has been gained concerning the pathogenesis , diagnosis , and treatment of the infection .
4-1	141-146	Since	_	_	_	_
4-2	147-150	the	abstract[10]	new[10]	_	_
4-3	151-156	first	abstract[10]	new[10]	_	_
4-4	157-168	description	abstract[10]	new[10]	_	_
4-5	169-171	of	abstract[10]	new[10]	_	_
4-6	172-175	the	abstract[10]|abstract[11]	new[10]|giv[11]	coref	5-1[0_11]
4-7	176-181	virus	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-8	182-184	in	abstract[10]	new[10]	_	_
4-9	185-189	1964	abstract[10]|time[12]	new[10]|new[12]	_	_
4-10	190-192	in	abstract[10]|time[12]	new[10]|new[12]	_	_
4-11	193-199	feline	abstract[10]|time[12]|abstract|object[15]	new[10]|new[12]|giv|new[15]	_	_
4-12	200-208	lymphoma	abstract[10]|time[12]|abstract|object[15]	new[10]|new[12]|new|new[15]	_	_
4-13	209-215	tissue	abstract[10]|time[12]|object[15]	new[10]|new[12]|new[15]	_	_
4-14	216-217	,	_	_	_	_
4-15	218-228	increasing	abstract[16]	new[16]	_	_
4-16	229-238	knowledge	abstract[16]	new[16]	_	_
4-17	239-242	has	_	_	_	_
4-18	243-247	been	_	_	_	_
4-19	248-254	gained	_	_	_	_
4-20	255-265	concerning	_	_	_	_
4-21	266-269	the	abstract[17]	new[17]	_	_
4-22	270-282	pathogenesis	abstract[17]	new[17]	_	_
4-23	283-284	,	_	_	_	_
4-24	285-294	diagnosis	abstract	new	_	_
4-25	295-296	,	_	_	_	_
4-26	297-300	and	_	_	_	_
4-27	301-310	treatment	abstract[19]	new[19]	_	_
4-28	311-313	of	abstract[19]	new[19]	_	_
4-29	314-317	the	abstract[19]|abstract[20]	new[19]|new[20]	coref	5-1[22_20]
4-30	318-327	infection	abstract[19]|abstract[20]	new[19]|new[20]	_	_
4-31	328-329	.	_	_	_	_

#Text=FeLV infection can lead to fatal diseases in cats with progressive infection .
5-1	330-334	FeLV	object|abstract[22]	giv|giv[22]	coref|coref|coref|coref	5-11[25_22]|6-16|5-11[25_22]|6-16
5-2	335-344	infection	abstract[22]	giv[22]	_	_
5-3	345-348	can	_	_	_	_
5-4	349-353	lead	_	_	_	_
5-5	354-356	to	_	_	_	_
5-6	357-362	fatal	abstract[23]	new[23]	_	_
5-7	363-371	diseases	abstract[23]	new[23]	_	_
5-8	372-374	in	abstract[23]	new[23]	_	_
5-9	375-379	cats	abstract[23]|animal[24]	new[23]|giv[24]	coref	11-15[53_24]
5-10	380-384	with	abstract[23]|animal[24]	new[23]|giv[24]	_	_
5-11	385-396	progressive	abstract[23]|animal[24]|abstract[25]	new[23]|giv[24]|giv[25]	coref	19-6[120_25]
5-12	397-406	infection	abstract[23]|animal[24]|abstract[25]	new[23]|giv[24]|giv[25]	_	_
5-13	407-408	.	_	_	_	_

#Text=Testing and eradication programs and the introduction of effective vaccines led to a decrease in FeLV prevalence in many countries in the last 30 years .
6-1	409-416	Testing	_	_	_	_
6-2	417-420	and	_	_	_	_
6-3	421-432	eradication	abstract|abstract[27]	new|new[27]	_	_
6-4	433-441	programs	abstract[27]	new[27]	_	_
6-5	442-445	and	_	_	_	_
6-6	446-449	the	event[28]	new[28]	_	_
6-7	450-462	introduction	event[28]	new[28]	_	_
6-8	463-465	of	event[28]	new[28]	_	_
6-9	466-475	effective	event[28]|object[29]	new[28]|new[29]	_	_
6-10	476-484	vaccines	event[28]|object[29]	new[28]|new[29]	_	_
6-11	485-488	led	_	_	_	_
6-12	489-491	to	_	_	_	_
6-13	492-493	a	event[30]	new[30]	coref	7-6[35_30]
6-14	494-502	decrease	event[30]	new[30]	_	_
6-15	503-505	in	event[30]	new[30]	_	_
6-16	506-510	FeLV	event[30]|abstract|abstract[32]	new[30]|giv|new[32]	coref|coref|coref|coref	7-10|7-9[37_32]|7-10|7-9[37_32]
6-17	511-521	prevalence	event[30]|abstract[32]	new[30]|new[32]	_	_
6-18	522-524	in	event[30]|abstract[32]	new[30]|new[32]	_	_
6-19	525-529	many	event[30]|abstract[32]|place[33]	new[30]|new[32]|new[33]	coref	8-2[38_33]
6-20	530-539	countries	event[30]|abstract[32]|place[33]	new[30]|new[32]|new[33]	_	_
6-21	540-542	in	event[30]|abstract[32]|place[33]	new[30]|new[32]|new[33]	_	_
6-22	543-546	the	event[30]|abstract[32]|place[33]|time[34]	new[30]|new[32]|new[33]|new[34]	_	_
6-23	547-551	last	event[30]|abstract[32]|place[33]|time[34]	new[30]|new[32]|new[33]|new[34]	_	_
6-24	552-554	30	event[30]|abstract[32]|place[33]|time[34]	new[30]|new[32]|new[33]|new[34]	_	_
6-25	555-560	years	event[30]|abstract[32]|place[33]|time[34]	new[30]|new[32]|new[33]|new[34]	_	_
6-26	561-562	.	_	_	_	_

#Text=However , more recently , the decrease of the FeLV prevalence has stagnated .
7-1	563-570	However	_	_	_	_
7-2	571-572	,	_	_	_	_
7-3	573-577	more	_	_	_	_
7-4	578-586	recently	_	_	_	_
7-5	587-588	,	_	_	_	_
7-6	589-592	the	event[35]	giv[35]	_	_
7-7	593-601	decrease	event[35]	giv[35]	_	_
7-8	602-604	of	event[35]	giv[35]	_	_
7-9	605-608	the	event[35]|abstract[37]	giv[35]|giv[37]	coref	9-11[0_37]
7-10	609-613	FeLV	event[35]|abstract|abstract[37]	giv[35]|giv|giv[37]	coref	8-9
7-11	614-624	prevalence	event[35]|abstract[37]	giv[35]|giv[37]	_	_
7-12	625-628	has	_	_	_	_
7-13	629-638	stagnated	_	_	_	_
7-14	639-640	.	_	_	_	_

#Text=In other countries , such as Denmark , FeLV is rarely detected nowadays .
8-1	641-643	In	_	_	_	_
8-2	644-649	other	place[38]	giv[38]	coref	10-14[49_38]
8-3	650-659	countries	place[38]	giv[38]	_	_
8-4	660-661	,	place[38]	giv[38]	_	_
8-5	662-666	such	place[38]	giv[38]	_	_
8-6	667-669	as	place[38]	giv[38]	_	_
8-7	670-677	Denmark	place[38]|place	giv[38]|new	_	_
8-8	678-679	,	_	_	_	_
8-9	680-684	FeLV	abstract	giv	coref	10-12
8-10	685-687	is	_	_	_	_
8-11	688-694	rarely	_	_	_	_
8-12	695-703	detected	_	_	_	_
8-13	704-712	nowadays	_	_	_	_
8-14	713-714	.	_	_	_	_

#Text=For the USA , Canada , and Australia , large prevalence studies have been published .
9-1	715-718	For	_	_	_	_
9-2	719-722	the	place[41]	new[41]	_	_
9-3	723-726	USA	place[41]	new[41]	_	_
9-4	727-728	,	_	_	_	_
9-5	729-735	Canada	place	new	_	_
9-6	736-737	,	_	_	_	_
9-7	738-741	and	_	_	_	_
9-8	742-751	Australia	place	new	_	_
9-9	752-753	,	_	_	_	_
9-10	754-759	large	event[45]	new[45]	coref	10-5[46_45]
9-11	760-770	prevalence	abstract|event[45]	giv|new[45]	coref	10-9[47_0]
9-12	771-778	studies	event[45]	new[45]	_	_
9-13	779-783	have	_	_	_	_
9-14	784-788	been	_	_	_	_
9-15	789-798	published	_	_	_	_
9-16	799-800	.	_	_	_	_

#Text=There have also been some recent studies on the prevalence of FeLV in single European countries .
10-1	801-806	There	_	_	_	_
10-2	807-811	have	_	_	_	_
10-3	812-816	also	_	_	_	_
10-4	817-821	been	_	_	_	_
10-5	822-826	some	event[46]	giv[46]	_	_
10-6	827-833	recent	event[46]	giv[46]	_	_
10-7	834-841	studies	event[46]	giv[46]	_	_
10-8	842-844	on	event[46]	giv[46]	_	_
10-9	845-848	the	event[46]|abstract[47]	giv[46]|giv[47]	coref	11-10[52_47]
10-10	849-859	prevalence	event[46]|abstract[47]	giv[46]|giv[47]	_	_
10-11	860-862	of	event[46]|abstract[47]	giv[46]|giv[47]	_	_
10-12	863-867	FeLV	event[46]|abstract[47]|abstract	giv[46]|giv[47]|giv	coref	11-12
10-13	868-870	in	event[46]|abstract[47]	giv[46]|giv[47]	_	_
10-14	871-877	single	event[46]|abstract[47]|place[49]	giv[46]|giv[47]|giv[49]	coref	15-10[92_49]
10-15	878-886	European	event[46]|abstract[47]|place[49]	giv[46]|giv[47]|giv[49]	_	_
10-16	887-896	countries	event[46]|abstract[47]|place[49]	giv[46]|giv[47]|giv[49]	_	_
10-17	897-898	.	_	_	_	_

#Text=However , there has been no pan-European study determining the current FeLV prevalence in domestic cats .
11-1	899-906	However	_	_	_	_
11-2	907-908	,	_	_	_	_
11-3	909-914	there	_	_	_	_
11-4	915-918	has	_	_	_	_
11-5	919-923	been	_	_	_	_
11-6	924-926	no	abstract[50]	new[50]	coref	16-4[96_50]
11-7	927-939	pan-European	abstract[50]	new[50]	_	_
11-8	940-945	study	abstract[50]	new[50]	_	_
11-9	946-957	determining	_	_	_	_
11-10	958-961	the	abstract[52]	giv[52]	coref	12-1[55_52]
11-11	962-969	current	abstract[52]	giv[52]	_	_
11-12	970-974	FeLV	abstract|abstract[52]	giv|giv[52]	coref	12-1
11-13	975-985	prevalence	abstract[52]	giv[52]	_	_
11-14	986-988	in	abstract[52]	giv[52]	_	_
11-15	989-997	domestic	abstract[52]|animal[53]	giv[52]|giv[53]	coref	12-16[59_53]
11-16	998-1002	cats	abstract[52]|animal[53]	giv[52]|giv[53]	_	_
11-17	1003-1004	.	_	_	_	_

#Text=FeLV prevalence can vary considerably depending on the composition of the investigated cat population ; feral or stray cats versus privately owned cats , cats in shelters or from breeders , clinically healthy cats or sick cats .
12-1	1005-1009	FeLV	abstract|abstract[55]	giv|giv[55]	coref|coref|coref|coref	13-27|14-9[72_55]|13-27|14-9[72_55]
12-2	1010-1020	prevalence	abstract[55]	giv[55]	_	_
12-3	1021-1024	can	_	_	_	_
12-4	1025-1029	vary	_	_	_	_
12-5	1030-1042	considerably	_	_	_	_
12-6	1043-1052	depending	_	_	_	_
12-7	1053-1055	on	_	_	_	_
12-8	1056-1059	the	abstract[56]	new[56]	_	_
12-9	1060-1071	composition	abstract[56]	new[56]	_	_
12-10	1072-1074	of	abstract[56]	new[56]	_	_
12-11	1075-1078	the	abstract[56]|abstract[58]	new[56]|new[58]	_	_
12-12	1079-1091	investigated	abstract[56]|abstract[58]	new[56]|new[58]	_	_
12-13	1092-1095	cat	abstract[56]|animal|abstract[58]	new[56]|new|new[58]	coref	19-25[127_0]
12-14	1096-1106	population	abstract[56]|abstract[58]	new[56]|new[58]	_	_
12-15	1107-1108	;	_	_	_	_
12-16	1109-1114	feral	animal[59]	giv[59]	coref	12-23[60_59]
12-17	1115-1117	or	animal[59]	giv[59]	_	_
12-18	1118-1123	stray	animal[59]	giv[59]	_	_
12-19	1124-1128	cats	animal[59]	giv[59]	_	_
12-20	1129-1135	versus	_	_	_	_
12-21	1136-1145	privately	_	_	_	_
12-22	1146-1151	owned	_	_	_	_
12-23	1152-1156	cats	animal[60]	giv[60]	coref	13-21[0_60]
12-24	1157-1158	,	animal[60]	giv[60]	_	_
12-25	1159-1163	cats	animal[60]	giv[60]	_	_
12-26	1164-1166	in	animal[60]	giv[60]	_	_
12-27	1167-1175	shelters	animal[60]|place	giv[60]|new	_	_
12-28	1176-1178	or	animal[60]	giv[60]	_	_
12-29	1179-1183	from	animal[60]	giv[60]	_	_
12-30	1184-1192	breeders	animal[60]|person	giv[60]|new	_	_
12-31	1193-1194	,	animal[60]	giv[60]	_	_
12-32	1195-1205	clinically	animal[60]	giv[60]	_	_
12-33	1206-1213	healthy	animal[60]	giv[60]	_	_
12-34	1214-1218	cats	animal[60]	giv[60]	_	_
12-35	1219-1221	or	animal[60]	giv[60]	_	_
12-36	1222-1226	sick	animal[60]	giv[60]	_	_
12-37	1227-1231	cats	animal[60]	giv[60]	_	_
12-38	1232-1233	.	_	_	_	_

#Text=In addition , preselection of the samples has an influence ; e. g. , if samples are obtained only from cats suspected of being infected with FeLV .
13-1	1234-1236	In	_	_	_	_
13-2	1237-1245	addition	_	_	_	_
13-3	1246-1247	,	_	_	_	_
13-4	1248-1260	preselection	abstract[63]	new[63]	_	_
13-5	1261-1263	of	abstract[63]	new[63]	_	_
13-6	1264-1267	the	abstract[63]|object[64]	new[63]|new[64]	coref	13-16[0_64]
13-7	1268-1275	samples	abstract[63]|object[64]	new[63]|new[64]	_	_
13-8	1276-1279	has	_	_	_	_
13-9	1280-1282	an	abstract[65]	new[65]	_	_
13-10	1283-1292	influence	abstract[65]	new[65]	_	_
13-11	1293-1294	;	_	_	_	_
13-12	1295-1297	e.	_	_	_	_
13-13	1298-1300	g.	_	_	_	_
13-14	1301-1302	,	_	_	_	_
13-15	1303-1305	if	_	_	_	_
13-16	1306-1313	samples	object	giv	_	_
13-17	1314-1317	are	_	_	_	_
13-18	1318-1326	obtained	_	_	_	_
13-19	1327-1331	only	_	_	_	_
13-20	1332-1336	from	_	_	_	_
13-21	1337-1341	cats	animal	giv	coref	16-17
13-22	1342-1351	suspected	_	_	_	_
13-23	1352-1354	of	_	_	_	_
13-24	1355-1360	being	_	_	_	_
13-25	1361-1369	infected	_	_	_	_
13-26	1370-1374	with	_	_	_	_
13-27	1375-1379	FeLV	animal	giv	coref	14-9
13-28	1380-1381	.	_	_	_	_

#Text=A recent meta-analysis suggested an indirect relation between FeLV prevalence and the yearly gross domestic product ( GDP ) per capita using purchasing power parity ( PPP ) , i. e. , the total value of all the goods and services produced by a country in a particular year , divided by the number of people living there and corrected for purchasing power using a “ basket of goods ” .
14-1	1382-1383	A	abstract[69]	new[69]	_	_
14-2	1384-1390	recent	abstract[69]	new[69]	_	_
14-3	1391-1404	meta-analysis	abstract[69]	new[69]	_	_
14-4	1405-1414	suggested	_	_	_	_
14-5	1415-1417	an	abstract[70]	new[70]	_	_
14-6	1418-1426	indirect	abstract[70]	new[70]	_	_
14-7	1427-1435	relation	abstract[70]	new[70]	_	_
14-8	1436-1443	between	abstract[70]	new[70]	_	_
14-9	1444-1448	FeLV	abstract[70]|abstract|abstract[72]|abstract[73]	new[70]|giv|giv[72]|new[73]	coref|coref|coref|coref|coref|coref|coref|coref|coref	15-4|15-5[0_72]|20-17[135_73]|15-4|15-5[0_72]|20-17[135_73]|15-4|15-5[0_72]|20-17[135_73]
14-10	1449-1459	prevalence	abstract[70]|abstract[72]|abstract[73]	new[70]|giv[72]|new[73]	_	_
14-11	1460-1463	and	abstract[70]|abstract[73]	new[70]|new[73]	_	_
14-12	1464-1467	the	abstract[70]|abstract[73]|quantity[75]	new[70]|new[73]|new[75]	_	_
14-13	1468-1474	yearly	abstract[70]|abstract[73]|quantity[75]	new[70]|new[73]|new[75]	_	_
14-14	1475-1480	gross	abstract[70]|abstract[73]|person|quantity[75]	new[70]|new[73]|new|new[75]	_	_
14-15	1481-1489	domestic	abstract[70]|abstract[73]|quantity[75]	new[70]|new[73]|new[75]	_	_
14-16	1490-1497	product	abstract[70]|abstract[73]|quantity[75]	new[70]|new[73]|new[75]	_	_
14-17	1498-1499	(	_	_	_	_
14-18	1500-1503	GDP	abstract	new	coref	20-21[136_0]
14-19	1504-1505	)	_	_	_	_
14-20	1506-1509	per	_	_	_	_
14-21	1510-1516	capita	_	_	_	_
14-22	1517-1522	using	_	_	_	_
14-23	1523-1533	purchasing	_	_	_	_
14-24	1534-1539	power	abstract|abstract[78]	new|new[78]	appos|coref|appos|coref	14-27[0_78]|14-63|14-27[0_78]|14-63
14-25	1540-1546	parity	abstract[78]	new[78]	_	_
14-26	1547-1548	(	_	_	_	_
14-27	1549-1552	PPP	abstract	giv	_	_
14-28	1553-1554	)	_	_	_	_
14-29	1555-1556	,	_	_	_	_
14-30	1557-1559	i.	_	_	_	_
14-31	1560-1562	e.	_	_	_	_
14-32	1563-1564	,	_	_	_	_
14-33	1565-1568	the	abstract[80]	new[80]	_	_
14-34	1569-1574	total	abstract[80]	new[80]	_	_
14-35	1575-1580	value	abstract[80]	new[80]	_	_
14-36	1581-1583	of	abstract[80]	new[80]	_	_
14-37	1584-1587	all	abstract[80]|object[81]	new[80]|new[81]	coref	14-69[0_81]
14-38	1588-1591	the	abstract[80]|object[81]	new[80]|new[81]	_	_
14-39	1592-1597	goods	abstract[80]|object[81]	new[80]|new[81]	_	_
14-40	1598-1601	and	abstract[80]	new[80]	_	_
14-41	1602-1610	services	abstract[80]|abstract	new[80]|new	_	_
14-42	1611-1619	produced	_	_	_	_
14-43	1620-1622	by	_	_	_	_
14-44	1623-1624	a	place[83]	new[83]	_	_
14-45	1625-1632	country	place[83]	new[83]	_	_
14-46	1633-1635	in	place[83]	new[83]	_	_
14-47	1636-1637	a	place[83]|time[84]	new[83]|new[84]	_	_
14-48	1638-1648	particular	place[83]|time[84]	new[83]|new[84]	_	_
14-49	1649-1653	year	place[83]|time[84]	new[83]|new[84]	_	_
14-50	1654-1655	,	_	_	_	_
14-51	1656-1663	divided	_	_	_	_
14-52	1664-1666	by	_	_	_	_
14-53	1667-1670	the	quantity[85]	new[85]	_	_
14-54	1671-1677	number	quantity[85]	new[85]	_	_
14-55	1678-1680	of	quantity[85]	new[85]	_	_
14-56	1681-1687	people	quantity[85]	new[85]	_	_
14-57	1688-1694	living	_	_	_	_
14-58	1695-1700	there	_	_	_	_
14-59	1701-1704	and	_	_	_	_
14-60	1705-1714	corrected	_	_	_	_
14-61	1715-1718	for	_	_	_	_
14-62	1719-1729	purchasing	_	_	_	_
14-63	1730-1735	power	abstract	giv	_	_
14-64	1736-1741	using	_	_	_	_
14-65	1742-1743	a	object[87]	new[87]	_	_
14-66	1744-1745	“	object[87]	new[87]	_	_
14-67	1746-1752	basket	object[87]	new[87]	_	_
14-68	1753-1755	of	object[87]	new[87]	_	_
14-69	1756-1761	goods	object[87]|object	new[87]|giv	_	_
14-70	1762-1763	”	object[87]	new[87]	_	_
14-71	1764-1765	.	_	_	_	_

#Text=However , no FeLV prevalence data were available for many European countries , or the data were obtained several years ago .
15-1	1766-1773	However	_	_	_	_
15-2	1774-1775	,	_	_	_	_
15-3	1776-1778	no	abstract[91]	new[91]	coref	15-15[93_91]
15-4	1779-1783	FeLV	abstract|abstract[91]	giv|new[91]	coref	16-14
15-5	1784-1794	prevalence	abstract|abstract[91]	giv|new[91]	_	_
15-6	1795-1799	data	abstract[91]	new[91]	_	_
15-7	1800-1804	were	_	_	_	_
15-8	1805-1814	available	_	_	_	_
15-9	1815-1818	for	_	_	_	_
15-10	1819-1823	many	place[92]	giv[92]	coref	17-7[106_92]
15-11	1824-1832	European	place[92]	giv[92]	_	_
15-12	1833-1842	countries	place[92]	giv[92]	_	_
15-13	1843-1844	,	_	_	_	_
15-14	1845-1847	or	_	_	_	_
15-15	1848-1851	the	abstract[93]	giv[93]	coref	19-20[126_93]
15-16	1852-1856	data	abstract[93]	giv[93]	_	_
15-17	1857-1861	were	_	_	_	_
15-18	1862-1870	obtained	_	_	_	_
15-19	1871-1878	several	time[94]	new[94]	_	_
15-20	1879-1884	years	time[94]	new[94]	_	_
15-21	1885-1888	ago	time[94]	new[94]	_	_
15-22	1889-1890	.	_	_	_	_

#Text=The aim of the present study was to determine the current prevalence of FeLV viraemia in cats that visit a veterinary facility .
16-1	1891-1894	The	abstract[95]	new[95]	_	_
16-2	1895-1898	aim	abstract[95]	new[95]	_	_
16-3	1899-1901	of	abstract[95]	new[95]	_	_
16-4	1902-1905	the	abstract[95]|abstract[96]	new[95]|giv[96]	coref	17-2[0_96]
16-5	1906-1913	present	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
16-6	1914-1919	study	abstract[95]|abstract[96]	new[95]|giv[96]	_	_
16-7	1920-1923	was	_	_	_	_
16-8	1924-1926	to	_	_	_	_
16-9	1927-1936	determine	_	_	_	_
16-10	1937-1940	the	abstract[97]	new[97]	coref	20-17[134_97]
16-11	1941-1948	current	abstract[97]	new[97]	_	_
16-12	1949-1959	prevalence	abstract[97]	new[97]	_	_
16-13	1960-1962	of	abstract[97]	new[97]	_	_
16-14	1963-1967	FeLV	abstract[97]|abstract|abstract[99]	new[97]|giv|new[99]	coref|coref|coref|coref	19-6|21-41[157_99]|19-6|21-41[157_99]
16-15	1968-1976	viraemia	abstract[97]|abstract[99]	new[97]|new[99]	_	_
16-16	1977-1979	in	abstract[97]|abstract[99]	new[97]|new[99]	_	_
16-17	1980-1984	cats	abstract[97]|abstract[99]|animal	new[97]|new[99]|giv	coref	17-5
16-18	1985-1989	that	_	_	_	_
16-19	1990-1995	visit	_	_	_	_
16-20	1996-1997	a	place[102]	new[102]	coref	18-14[111_102]
16-21	1998-2008	veterinary	person|place[102]	new|new[102]	coref	18-15
16-22	2009-2017	facility	place[102]	new[102]	_	_
16-23	2018-2019	.	_	_	_	_

#Text=The study protocol included cats from 32 European countries in the survey .
17-1	2020-2023	The	abstract[104]	new[104]	_	_
17-2	2024-2029	study	abstract|abstract[104]	giv|new[104]	_	_
17-3	2030-2038	protocol	abstract[104]	new[104]	_	_
17-4	2039-2047	included	_	_	_	_
17-5	2048-2052	cats	animal	giv	coref	18-8[109_0]
17-6	2053-2057	from	_	_	_	_
17-7	2058-2060	32	place[106]	giv[106]	coref	20-24[137_106]
17-8	2061-2069	European	place[106]	giv[106]	_	_
17-9	2070-2079	countries	place[106]	giv[106]	_	_
17-10	2080-2082	in	place[106]	giv[106]	_	_
17-11	2083-2086	the	place[106]|abstract[107]	giv[106]|new[107]	_	_
17-12	2087-2093	survey	place[106]|abstract[107]	giv[106]|new[107]	_	_
17-13	2094-2095	.	_	_	_	_

#Text=In order to avoid any preselection of the cats ( apart from visiting a veterinary facility ) , 10 animals arriving consecutively at each facility were tested independently of the reason for the veterinary appointment .
18-1	2096-2098	In	_	_	_	_
18-2	2099-2104	order	_	_	_	_
18-3	2105-2107	to	_	_	_	_
18-4	2108-2113	avoid	_	_	_	_
18-5	2114-2117	any	abstract[108]	new[108]	_	_
18-6	2118-2130	preselection	abstract[108]	new[108]	_	_
18-7	2131-2133	of	abstract[108]	new[108]	_	_
18-8	2134-2137	the	abstract[108]|animal[109]	new[108]|giv[109]	_	_
18-9	2138-2142	cats	abstract[108]|animal[109]	new[108]|giv[109]	_	_
18-10	2143-2144	(	_	_	_	_
18-11	2145-2150	apart	_	_	_	_
18-12	2151-2155	from	_	_	_	_
18-13	2156-2164	visiting	_	_	_	_
18-14	2165-2166	a	place[111]	giv[111]	coref	18-24[113_111]
18-15	2167-2177	veterinary	person|place[111]	giv|giv[111]	coref	18-34
18-16	2178-2186	facility	place[111]	giv[111]	_	_
18-17	2187-2188	)	_	_	_	_
18-18	2189-2190	,	_	_	_	_
18-19	2191-2193	10	animal[112]	new[112]	_	_
18-20	2194-2201	animals	animal[112]	new[112]	_	_
18-21	2202-2210	arriving	_	_	_	_
18-22	2211-2224	consecutively	_	_	_	_
18-23	2225-2227	at	_	_	_	_
18-24	2228-2232	each	place[113]	giv[113]	_	_
18-25	2233-2241	facility	place[113]	giv[113]	_	_
18-26	2242-2246	were	_	_	_	_
18-27	2247-2253	tested	_	_	_	_
18-28	2254-2267	independently	_	_	_	_
18-29	2268-2270	of	_	_	_	_
18-30	2271-2274	the	abstract[114]	new[114]	_	_
18-31	2275-2281	reason	abstract[114]	new[114]	_	_
18-32	2282-2285	for	abstract[114]	new[114]	_	_
18-33	2286-2289	the	abstract[114]|event[116]	new[114]|new[116]	_	_
18-34	2290-2300	veterinary	abstract[114]|person|event[116]	new[114]|giv|new[116]	_	_
18-35	2301-2312	appointment	abstract[114]|event[116]	new[114]|new[116]	_	_
18-36	2313-2314	.	_	_	_	_

#Text=Risk and protective factors for FeLV infection were determined using the demographic , husbandry , clinical as well as FeLV vaccination history data from each cat .
19-1	2315-2319	Risk	abstract	new	_	_
19-2	2320-2323	and	_	_	_	_
19-3	2324-2334	protective	abstract[118]	new[118]	_	_
19-4	2335-2342	factors	abstract[118]	new[118]	_	_
19-5	2343-2346	for	abstract[118]	new[118]	_	_
19-6	2347-2351	FeLV	abstract[118]|animal|abstract[120]	new[118]|giv|giv[120]	coref|coref	19-20|19-20
19-7	2352-2361	infection	abstract[118]|abstract[120]	new[118]|giv[120]	_	_
19-8	2362-2366	were	_	_	_	_
19-9	2367-2377	determined	_	_	_	_
19-10	2378-2383	using	_	_	_	_
19-11	2384-2387	the	abstract[121]	new[121]	_	_
19-12	2388-2399	demographic	abstract[121]	new[121]	_	_
19-13	2400-2401	,	_	_	_	_
19-14	2402-2411	husbandry	abstract	new	_	_
19-15	2412-2413	,	_	_	_	_
19-16	2414-2422	clinical	_	_	_	_
19-17	2423-2425	as	_	_	_	_
19-18	2426-2430	well	_	_	_	_
19-19	2431-2433	as	_	_	_	_
19-20	2434-2438	FeLV	animal|abstract[126]	giv|giv[126]	coref|coref|coref|coref	20-4[129_126]|20-18|20-4[129_126]|20-18
19-21	2439-2450	vaccination	abstract|abstract[126]	new|giv[126]	coref	20-40
19-22	2451-2458	history	abstract|abstract[126]	new|giv[126]	_	_
19-23	2459-2463	data	abstract[126]	giv[126]	_	_
19-24	2464-2468	from	abstract[126]	giv[126]	_	_
19-25	2469-2473	each	abstract[126]|animal[127]	giv[126]|giv[127]	_	_
19-26	2474-2477	cat	abstract[126]|animal[127]	giv[126]|giv[127]	_	_
19-27	2478-2479	.	_	_	_	_

#Text=Furthermore , using our data , we tested the recently postulated hypothesis of a correlation between the FeLV prevalence and the GDP in European countries , and extended the analysis to test also for a potential correlation with FeLV vaccination rates .
20-1	2480-2491	Furthermore	_	_	_	_
20-2	2492-2493	,	_	_	_	_
20-3	2494-2499	using	_	_	_	_
20-4	2500-2503	our	person|abstract[129]	acc|giv[129]	ana|ana	20-7|20-7
20-5	2504-2508	data	abstract[129]	giv[129]	_	_
20-6	2509-2510	,	_	_	_	_
20-7	2511-2513	we	person	giv	_	_
20-8	2514-2520	tested	_	_	_	_
20-9	2521-2524	the	abstract[131]	new[131]	_	_
20-10	2525-2533	recently	abstract[131]	new[131]	_	_
20-11	2534-2544	postulated	abstract[131]	new[131]	_	_
20-12	2545-2555	hypothesis	abstract[131]	new[131]	_	_
20-13	2556-2558	of	abstract[131]	new[131]	_	_
20-14	2559-2560	a	abstract[131]|abstract[132]	new[131]|new[132]	coref	20-35[139_132]
20-15	2561-2572	correlation	abstract[131]|abstract[132]	new[131]|new[132]	_	_
20-16	2573-2580	between	abstract[131]|abstract[132]	new[131]|new[132]	_	_
20-17	2581-2584	the	abstract[131]|abstract[132]|abstract[134]|abstract[135]	new[131]|new[132]|giv[134]|giv[135]	_	_
20-18	2585-2589	FeLV	abstract[131]|abstract[132]|abstract|abstract[134]|abstract[135]	new[131]|new[132]|giv|giv[134]|giv[135]	coref	20-39
20-19	2590-2600	prevalence	abstract[131]|abstract[132]|abstract[134]|abstract[135]	new[131]|new[132]|giv[134]|giv[135]	_	_
20-20	2601-2604	and	abstract[131]|abstract[132]|abstract[135]	new[131]|new[132]|giv[135]	_	_
20-21	2605-2608	the	abstract[131]|abstract[132]|abstract[135]|abstract[136]	new[131]|new[132]|giv[135]|giv[136]	_	_
20-22	2609-2612	GDP	abstract[131]|abstract[132]|abstract[135]|abstract[136]	new[131]|new[132]|giv[135]|giv[136]	_	_
20-23	2613-2615	in	abstract[131]|abstract[132]|abstract[135]|abstract[136]	new[131]|new[132]|giv[135]|giv[136]	_	_
20-24	2616-2624	European	abstract[131]|abstract[132]|abstract[135]|abstract[136]|place[137]	new[131]|new[132]|giv[135]|giv[136]|giv[137]	_	_
20-25	2625-2634	countries	abstract[131]|abstract[132]|abstract[135]|abstract[136]|place[137]	new[131]|new[132]|giv[135]|giv[136]|giv[137]	_	_
20-26	2635-2636	,	_	_	_	_
20-27	2637-2640	and	_	_	_	_
20-28	2641-2649	extended	_	_	_	_
20-29	2650-2653	the	abstract[138]	new[138]	_	_
20-30	2654-2662	analysis	abstract[138]	new[138]	_	_
20-31	2663-2665	to	_	_	_	_
20-32	2666-2670	test	_	_	_	_
20-33	2671-2675	also	_	_	_	_
20-34	2676-2679	for	_	_	_	_
20-35	2680-2681	a	abstract[139]	giv[139]	_	_
20-36	2682-2691	potential	abstract[139]	giv[139]	_	_
20-37	2692-2703	correlation	abstract[139]	giv[139]	_	_
20-38	2704-2708	with	abstract[139]	giv[139]	_	_
20-39	2709-2713	FeLV	abstract[139]|abstract|abstract[142]	giv[139]|giv|new[142]	coref|coref	21-41|21-41
20-40	2714-2725	vaccination	abstract[139]|abstract|abstract[142]	giv[139]|giv|new[142]	_	_
20-41	2726-2731	rates	abstract[139]|abstract[142]	giv[139]|new[142]	_	_
20-42	2732-2733	.	_	_	_	_

#Text=For minimally invasive sample collection and to avoid bias by requesting blood collection , saliva swabs were collected and analysed by RT-qPCR ; the detection of viral RNA by RT-qPCR in saliva was shown to be an excellent measure of FeLV viraemia .
21-1	2734-2737	For	_	_	_	_
21-2	2738-2747	minimally	abstract[144]	new[144]	coref	21-12[147_144]
21-3	2748-2756	invasive	abstract[144]	new[144]	_	_
21-4	2757-2763	sample	object|abstract[144]	new|new[144]	_	_
21-5	2764-2774	collection	abstract[144]	new[144]	_	_
21-6	2775-2778	and	_	_	_	_
21-7	2779-2781	to	_	_	_	_
21-8	2782-2787	avoid	_	_	_	_
21-9	2788-2792	bias	abstract	new	_	_
21-10	2793-2795	by	_	_	_	_
21-11	2796-2806	requesting	_	_	_	_
21-12	2807-2812	blood	substance|abstract[147]	new|giv[147]	_	_
21-13	2813-2823	collection	abstract[147]	giv[147]	_	_
21-14	2824-2825	,	_	_	_	_
21-15	2826-2832	saliva	abstract|object[149]	new|new[149]	coref|coref	21-32|21-32
21-16	2833-2838	swabs	object[149]	new[149]	_	_
21-17	2839-2843	were	_	_	_	_
21-18	2844-2853	collected	_	_	_	_
21-19	2854-2857	and	_	_	_	_
21-20	2858-2866	analysed	_	_	_	_
21-21	2867-2869	by	_	_	_	_
21-22	2870-2877	RT-qPCR	object	new	coref	21-30[153_0]
21-23	2878-2879	;	_	_	_	_
21-24	2880-2883	the	abstract[151]	new[151]	_	_
21-25	2884-2893	detection	abstract[151]	new[151]	_	_
21-26	2894-2896	of	abstract[151]	new[151]	_	_
21-27	2897-2902	viral	abstract[151]|substance[152]	new[151]|new[152]	_	_
21-28	2903-2906	RNA	abstract[151]|substance[152]	new[151]|new[152]	_	_
21-29	2907-2909	by	abstract[151]	new[151]	_	_
21-30	2910-2917	RT-qPCR	abstract[151]|object[153]	new[151]|giv[153]	_	_
21-31	2918-2920	in	abstract[151]|object[153]	new[151]|giv[153]	_	_
21-32	2921-2927	saliva	abstract[151]|object[153]|substance	new[151]|giv[153]|giv	_	_
21-33	2928-2931	was	_	_	_	_
21-34	2932-2937	shown	_	_	_	_
21-35	2938-2940	to	_	_	_	_
21-36	2941-2943	be	_	_	_	_
21-37	2944-2946	an	abstract[155]	new[155]	_	_
21-38	2947-2956	excellent	abstract[155]	new[155]	_	_
21-39	2957-2964	measure	abstract[155]	new[155]	_	_
21-40	2965-2967	of	abstract[155]	new[155]	_	_
21-41	2968-2972	FeLV	abstract[155]|abstract|abstract[157]	new[155]|giv|giv[157]	_	_
21-42	2973-2981	viraemia	abstract[155]|abstract[157]	new[155]|giv[157]	_	_
21-43	2982-2983	.	_	_	_	_
